Jeffrey M. Isner, MD; William A. Dietz, MD
In large part, the heart has profited from advances in recombinant DNA technology. The introduction of tissue plasminogen activator, for example, has been widely regarded as a major therapeutic breakthrough in the treatment of acute myocardial infarction; nearly routine use of this agent in appropriate individuals is anticipated to reduce infarct size and thereby improve residual ventricular function and survival (1). Subsequent development of similar agents with improved clot-specific lytic activity is expected to further reduce systemic toxicity so that the reduced risk-benefit ratio associated with such drug use could allow its use on an even more widespread basis.
Jeffrey M. Isner, William A. Dietz. Cardiovascular Consequences of Recombinant DNA Technology: Interleukin-2. Ann Intern Med. 1988;109:933–935. doi: 10.7326/0003-4819-109-12-933
Download citation file:
Published: Ann Intern Med. 1988;109(12):933-935.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use